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Research
Trichloroethylene (TRI) is a chlorinated   
solvent that has been used as a degreaser and 
as an intermediate in synthesizing other chem-
icals. Occupational TRI exposure is declining 
in industrialized countries because of techno-
logical innovation and legislation (Grote et al. 
2003), but it is increasing in emerging indus-
trialized countries, especially in Asia (Huang 
et al. 2002). TRI exposure has been associ-
ated with rat renal (Mensing et al. 2002) and 
mouse liver injury (Ramdhan et al. 2008), 
impaired reproductive function in male mice 
(Forkert et al. 2002), auto  immune hepatitis 
in the autoimmune-prone MRL mouse model 
(Griffin et al. 2000), and allergic hepatitis in 
the guinea pig maximization test (Tang et al. 
2008). Recently, occupational exposure to 
TRI was associated with severe hypersensitive 
skin damage and impaired hepatic function 
(Kamijima et al. 2007).
TRI is metabolized through oxidation 
by cytochrome P450 (CYP) isozymes such 
as CYP1A1/2, CYP2B1/2, CYP2C11, and 
CYP2E1 (Kim and Ghanayem 2006; Lash 
et al. 2000; Nakajima et al. 1990). CYP2E1 
is the most important enzyme in the conver-
sion of TRI to chloral hydrate through inter-
mediate metabolite(s) formation (Nakajima 
et al. 1992; Ramdhan et al. 2008), which is 
rapidly metabolized to trichloro  acetic acid 
(TCA) by aldehyde dehydrogenase (ALDH) 
or to trichloro  ethanol (TCE) by alcohol dehy-
drogenase (ADH). TCE can be converted to 
TCA by ADH and ALDH via chloral hydrate. 
In addition, a small portion of TRI is conju-
gated by glutathione S-transferase (GST) to 
form S-(dichlorovinyl) glutathione and further 
metabolized to S-(1,2-dichlorovinyl)-l cysteine, 
which is considered a kidney carcinogen (Lash 
et al. 2000). An intermediate metabolite(s) of 
TRI to chloral hydrate is thought to induce 
hepatic damage (Nakajima et al. 1988). 
Peroxisome proliferators function as 
ligands for the peroxisome proliferator- 
activated receptor α (PPARα) (Issemann and 
Green 1990), a nuclear receptor that regu-
lates genes involved in fatty acid transport and 
β-oxidation, resulting in increased fatty acid 
catabolism and increases in the number and 
size of peroxisomes in the livers of exposed 
mice or rats (Reddy and Krishnakantha 1975). 
TCA and DCA both activate PPARα in 
the liver, but other TRI metabolites do not 
(Maloney and Waxman 1999). Laughter et al. 
(2004) also reported the activation of PPARα 
by TRI, TCA, or DCA treatment in PPARα 
wild-type mice, judging from the induction 
of PPARα-related gene expressions, but not 
in Pparα-null mice. In addition, Ramdhan 
et al. (2008) reported that PPARα was acti-
vated after TRI exposure in wild-type but not 
CYP2E1-null mice, which they attributed to a 
lack of CYP2E1-mediated production of TCA.
Whether activation of PPARα is involved in 
TRI-induced liver injury remains to be clarified. 
PPARα activation is accompanied by increased 
hepatic lipid turnover via the β-oxidation sys-
tem, which reduces lipid accumulation that can 
result in hepatic toxicity (Harano et al. 2006). 
PPARα activation also can inhibit proinflam-
matory nuclear factor-kappa B (NFκB) by 
interacting with the p65 and p50 hetero  dimer 
(Delerive et al. 1999), and anti-inflammatory 
effects via PPARα-mediated inhibition of 
NFκB DNA binding activity have been dem-
onstrated in human hepato  cytes (Hirano et al. 
2002). However, although the consequences 
of PPARα activation in the mouse liver is rela-
tively well defined (Mandard et al. 2004), the 
consequences of human PPARα activation in 
response to TRI and other peroxisome pro-
liferators is still poorly understood.
Another PPAR subtype, PPARγ, regu-
lates genes involved in adipogenesis and 
lipid metabolism (Berger and Moller 2002). 
PPARγ may also be involved in TRI-induced 
hepatosteatosis, as TCA also activates mouse 
PPARγ (Maloney and Waxman 1999), and 
guinea pigs suffering from TRI-induced 
toxic liver injury showed fatty changes of 
the liver (Tang et al. 2008). In the present 
study, we investigated TRI-induced sub  acute 
hepato  toxicity in mPPARα, Pparα-null and 
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Ba c k g r o u n d: Trichloroacetic acid, an oxidative metabolite of trichloroethylene (TRI), is a ligand 
of the peroxisome proliferator-activated receptor α (PPAR) α, which is involved in lipid homeo  stasis 
and anti-inflammation.
OB j e c t i v e: We examined the role of mouse and human PPARα in TRI-induced hepatic steatosis 
and toxicity.
Me t h o d s : Male wild-type (mPPARα), Pparα-null, and humanized PPARα (hPPARα) mice on 
an Sv/129 background were exposed via inhalation to 0, 1,000, and 2,000 ppm TRI for 8 hr/day 
for 7 days. We assessed TRI-induced steatosis or hepatic damage through biochemical and histo-
pathological measurements.
Re s u l t s: Plasma alanine aminotransferase and aspartate aminotransferase activities increased in 
all mouse lines after exposure to 1,000 and 2,000 ppm TRI. Exposure induced hepato  cyte necrosis   
and inflammatory cells in all mouse lines, but hepatic lipid accumulation was observed only in 
Pparα-null and hPPARα mice. No differences were observed in TRI-mediated induction of hepatic 
PPARα target genes except for a few genes that differed between mPPARα and hPPARα mice. 
However, TRI significantly increased expression of triglyceride (TG)-synthesizing enzymes, diacyl-
glicerol acyltransferases, and PPARγ in Pparα-null and hPPARα mice, which may account for the 
increased TG in their livers. TRI exposure elevated nuclear factor-kappa B (NFκB) p52 mRNA and 
protein in all mice regardless of PPARα genotype. 
Co n c l u s i o n s: NFκB-p52 is a candidate molecular marker for inflammation caused by TRI, and 
PPARα may be involved in TRI-induced hepatosteatosis. However, human PPARα may afford 
only weak protection against TRI-mediated effects compared with mouse PPARα.
Key w o r d s : CYP2E1, fatty acid β-oxidation, hepatotoxicity, PPARα, steatosis, trichloroethylene. 
Environ Health Perspect 118:1557–1563 (2010).  doi:10.1289/ehp.1001928 [Online 13 August 2010]Ramdhan et al.
1558  v o l u m e  118 | n u m b e r 11 | November 2010  •  Environmental Health Perspectives
humanized PPARα (hPPARα) mice to clarify 
differences in the roles of human and mouse 
PPARα in TRI toxicity.
Materials and Methods
Chemicals. TRI was provided by the Japan 
Association for Hygiene of Chlorinated 
Solvents, and its purity was determined to be 
at least 99% as judged by gas chromatography-
mass spectrometry (GC-MS). All other chemi-
cals were purchased from commercial sources 
and were of the highest purity available.
Animals. This study was conducted accord-
ing to the Animal Experimental Guidelines of 
the Nagoya University Graduate School of 
Medicine. Male wild-type (mPPARα), Pparα-
null (Lee et al. 1995), and hPPARαTet-OFF 
(hPPARα) (Cheung et al. 2004) mice on 
an Sv/129 genetic background were bred as 
described elsewhere (Nakamura et al. 2009) 
and reared at the Institute of Laboratory 
Animal Research (Nagoya University 
Graduate School of Medicine). The expression 
of human PPARα cDNA in hPPARαTet-OFF 
mice is limited to hepatocytes and is under 
the control of the tetracycline regulatory sys-
tem, as described by Cheung et al. (2004). All 
mice were housed in a room under a 12:12 hr 
light:dark cycle (lights on at 0900 hours 
and off at 2100 hours), with stable relative 
humidity (57–60%) and a constant tempera-
ture (23–25°C). Food and water were pro-
vided ad libitum, and all animals were treated 
humanely and with regard for the alleviation 
of suffering. When the mice were 10 weeks 
of age, each strain was randomly divided into 
three groups of six animals each.
TRI exposure. Each group of mice was 
exposed to 0, 1,000, or 2,000 ppm TRI 
[equivalent to 0, 800, and 1,600 mg/kg/day 
by gavage, respectively (Griffin et al. 2000)] or 
fresh air in an inhalation chamber for 8 hr/day 
over 7 consecutive days, as described previously 
(Ramdhan et al. 2008). In PPARα wild-type 
mice, TRI metabo  lism was previously shown 
to be saturated with exposure to approximately 
1,000 ppm (Ramdhan et al. 2008), but we 
evaluated exposure to 1,000 and 2,000 ppm 
because of limited information concerning TRI 
metabolism in Pparα-null and hPPARα mice. 
We studied exposure by inhalation, because 
this is the most common route of occupational 
exposure in humans. Occupational exposures 
are generally much lower than exposures used 
in this research but may approach these levels 
in some cases, for example, during defatting 
processes using immersion tanks (Nakajima 
et al. 1980). Mice were moved to individual 
metal metabolism cages to collect urine sam-
ples after 7 days, and were sacrificed by exsan-
guination through the abdominal aorta under 
pento  barbital anesthesia the following day. 
Plasma was separated from whole blood by 
centrifugation at 3,000 rpm for 10 min. The 
liver was carefully dissected out and immedi-
ately weighed, and a small section was excised 
from the median lobe of each mouse and fixed 
in 10% neutral buffered formalin.
Plasma aminotransferase activities.We 
meas  ured aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) activities by 
the colorimetric method using a Transaminase 
C II Test Kit (Wako, Osaka, Japan).
Triglyceride concentration. Lipid was 
extracted from livers using the method of 
Folch et al. (1957), and hepatic and plasma 
tri  glyceride (TG) were measured by the colori-
metric method using TG-IE kits (Wako). 
Urinary metabolites. We measured urinary   
TCA and TCE concentrations by gas chroma-
tography-mass spectrometry (GC-MS) (6890N 
gas chromatograph, 5975 Mass Selective 
Detector, 7683 Automatic Liquid Sampler; 
Agilent Technologies, Santa Clara, CA, USA), 
as described previously (Ramdhan et al. 2008).
Histopathology evaluation. Tissue blocks 
were embedded in paraffin and 5-μm sec-
tions were mounted on glass slides and 
stained with hematoxylin and eosin (H&E). 
Photomicrographic images were captured on 
a BZ-8000 fluorescence microscope micro-
scope (Keyence, Osaka, Japan). We identi-
fied stea  tosis based on the presence of vacuoles 
consistent with lipid accumulation (Kumar 
et al. 2007); steatosis was classified as macro-
vesicular stea  tosis if the nucleus was displaced 
by the vacuole or as micro  vesicular steatosis 
if the nucleus remained in the center of the 
hepato  cyte (Brunt et al. 1999). Hepatocyte 
proliferation was classified based on the pres-
ence of enlarged hepatocytes with prominent 
eosinophilic cytoplasm (Yang et al. 2007). 
Cells with eosinophilic cytoplasm and pycnotic 
or karyolitic nuclei were designated as necrotic.
Histopathological findings in 20 randomly 
selected 200× microscopic fields per section 
were scored (Brunt et al. 1999; Okiyama et al. 
2009) for steatosis [0, none; 1, mild (5–33% of 
parenchymal involvement of steatosis); 2, mod-
erate (33–66%); or 3, severe (> 66%)]; necrotic 
cells [0, no necrosis; 1, minimal (only occa-
sional necrotic cells in any lobule); 2, mild (less 
than one-third of the lobular structure affected); 
3, moderate (one-third to two-thirds of lobular 
structure affected); or 4, severe (greater than two-
thirds of the lobular structure affected)]; lobular 
and portal tract inflammation [0, none; 1, mild 
(< 2 foci/field); 2, moderate (2–4 foci/field); or 
3, severe (> 4 foci/field)]; and hepatocyte prolif-
eration (0, absent; 1, present).
Real-time quantitative polymerase chain 
reaction (PCR). We isolated total RNA 
from whole liver using the RNeasy Mini Kit 
(QIAGEN, Tokyo, Japan). Real-time PCR 
analysis was performed as described else-
where (Ito et al. 2007; Nakamura et al. 2009; 
Ramdhan et al. 2008).
Western blot analysis. A section of liver 
from each mouse was homogenized with 
three volumes of 10 mM phosphate buffer 
(pH 7.4) containing 0.25 M sucrose. The 
nuclear fraction (derived from both hepato-
cytes and non  parenchymal cells) was extracted 
using a CelLytic NuCLEAR Extraction Kit 
(Sigma, Tokyo, Japan). Nuclear fractions 
(NFκB-p65, NFκB-p50, NFκB-p52, and 
PPARα) and liver homogenates (other pro-
teins include CYP2E1 and ALDH2) were 
subjected to 10% or 12.5% polyacrylamide 
gel electrophoresis, as described elsewhere 
(Aoyama et al. 1998; Kamijo et al. 2007; 
Ramdhan et al. 2008).
Statistical analysis. Data are expressed as 
mean ± SD. We used the Tukey-Kramer HSD 
Table 1. Body and liver weights and concentrations of urinary TRI metabolites, transaminase, and plasma and hepatic TG in mPPARα, Pparα-null, and hPPARα 
mice after TRI exposure.
Mouse 
genotype n
TRI 
(ppm)
Weight (g) Liver/body 
weight ratio 
TRI metabolites Transaminase TG
Body Liver TCE (mg) TCA (mg) AST (IU/L) ALT (IU/L) Plasma (mg/dL) Liver (mg/g)
mPPARα 6 0 25.1 ± 0.7 1.17 ± 0.04 4.68 ± 0.17 ND ND 19.9 ± 1.3 6.1 ± 0.8 70.4 ± 17.7 25.7 ± 5.1
6 1,000 25.0 ± 2.3 1.62 ± 0.15# 6.47 ± 0.16# 4.8 ± 3.7 0.49 ± 0.39## 30.4 ± 3.6# 8.6 ± 1.8# 66.7 ± 22.8 31.3 ± 4.3
6 2,000 26.1 ± 1.3 1.74 ± 0.11# 6.67 ± 0.48# 6.2 ± 2.0 0.49 ± 0.14## 32.4 ± 10.1# 9.2 ± 1.0# 86.0 ± 25.0 33.7 ± 8.5
Pparα-null 5 0 23.6 ± 1.5 1.22 ± 0.09 5.19 ± 0.31* ND ND 18.4 ± 1.0 6.0 ± 1.4 77.3 ± 12.7 35.0 ± 2.7*
5 1,000 22.8 ± 0.7 1.47 ± 0.14# 6.43 ± 0.44# 7.5 ± 1.1 0.26 ± 0.09## 26.3 ± 3.1# 9.1 ± 0.9# 116.4 ± 24.7 51.2 ± 6.9
5 2,000 23.6 ± 1.8 1.67 ± 0.15# 7.05 ± 0.14#,† 6.4 ± 4.1 0.28 ± 0.17## 32.9 ± 6.6# 10.5 ± 1.3# 102.5 ± 32.4 74.7 ± 22.0#
hPPARα 6 0 21.6 ± 0.7*,** 1.09 ± 0.06** 5.04 ± 0.29 ND ND 21.0 ± 1.8 5.6 ± 1.0 107.0 ± 30.7* 45.6 ± 13.4*,**
6 1,000 21.9 ± 2.0 1.40 ± 0.16# 6.39 ± 0.22# 5.7 ± 2.4 0.53 ± 0.17 26.6 ± 5.3# 8.1 ± 1.2# 81.1 ± 17.1 72.2 ± 14.4#
6 2,000 20.9 ± 1.4 1.44 ± 0.25# 6.98 ± 0.87# 5.0 ± 1.9 0.43 ± 0.21 32.0 ± 5.6# 9.0 ± 2.0# 82.3 ± 35.0 85.4 ± 14.0#
ND, not detected. Values are mean ± SD. TRI 0 ppm is the control.
*p < 0.05 compared with the mPPARα control group. **p < 0.05 compared with the Pparα-null control group. #p < 0.05 compared with the the control group of the same genotype. 
##p < 0.05 compared with the same treatment between genotypes. †p < 0.05 between the 1,000 and 2,000 ppm TRI doses. Role of PPARα in trichloroethylene-induced steatosis
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test to compare genotype effects (vs. wild-type 
controls) and exposure effects in each strain. 
TCA and TCE were below the detection 
limit in all control groups, and metabolism 
was saturated at 1,000 ppm. Therefore, we 
compared levels of TCA and TCE, respec-
tively, in exposed mice (1,000 and 2,000 ppm 
combined) between genotype groups. 
Histopathologic scores were compared using a 
non  parametric method (Steel-Dwass method). 
The alpha level for statistical significance was 
set at p < 0.05.
Results
Liver and body weight. We found significant 
differences among control (unexposed) mice 
according to genotype (Table 1). Specifically, 
the mean body weight of hPPARα mice was 
14% less and 8.5% less than mPPARα and 
Pparα-null mice, respectively, and the mean 
liver weight of hPPARα mice was 11% less 
than Pparα-null mice; the liver/body weight 
ratio of Pparα-null mice was 11% higher 
than in mPPARα mice. TRI at 1,000 and 
2,000 ppm significantly increased liver weight 
in the three mouse lines, and the increases 
were almost the same: 38% and 49% in 
mPPARα mice; 20% and 37% in Pparα-null 
mice; and 28% and 32% in hPPARα mice, 
respectively. However, the increases were not 
significantly different between TRI doses 
within each strain. Liver/body weight ratios 
were also significantly increased with TRI 
exposure at 1,000 and 2,000 ppm relative to 
controls (38% and 43% in mPPARα; 24% 
and 36% in Pparα-null, and 27% and 39% 
in hPPARα mice, respectively), with a signifi-
cant difference between 2,000 and 1,000 ppm 
exposures in Pparα-null mice.
Urinary metabolites. We observed no 
differences in the volume of urine samples 
collected according to genotype or exposure 
concentration (data not shown). TCA and 
TCE levels were below the detection limit in 
all control mice (Table 1). TCA and TCE 
were detectable in all TRI-exposed mice but 
were not significantly different between the 
two TRI exposures within strains. TCA con-
centrations were significantly lower and TCE 
concentrations tended to be higher in exposed 
Pparα-null mice relative to exposed mPPARα 
mice. Mean concentrations of total TRI 
metabo  lites (TCA plus TCE) in mPPARα, 
Pparα-null, and hPPARα mice were 79.1, 
97.9, and 73.8 mmol, respectively, with no 
significant differences among the genotypes.
Biochemical changes. AST and ALT liver 
injury biomarkers varied < 10% among control 
mice in each strain (Table 1). Plasma ALT and 
AST levels were significantly increased in all 
exposed mice relative to controls (41–74% and 
36–79% higher, respectively), and mean levels 
within each group were higher, although not 
significantly different, with exposure to 2,000 
versus 1,000 ppm TRI.
TG in plasma and liver. In unexposed 
mice, we observed significantly higher plasma 
TG levels in hPPARα versus mPPARα mice 
(52%), and significantly higher liver TG levels 
in hPPARα mice versus mPPARα and Pparα-
null mice (77% and 30%, respectively) and 
in Pparα-null versus mPPARα mice (36%) 
(Table 1). Relative to unexposed mice, liver 
TG levels were significantly higher in Pparα-
null mice exposed to 2,000 ppm TRI (113%) 
and in hPPARα mice exposed to 1,000 (58%) 
and 2,000 ppm (87%) TRI. However, there 
were no significant differences in mean 
plasma or liver TG concentrations between 
2,000-ppm and 1,000-ppm TRI mice within 
groups. Hepatic TG levels were significantly 
correlated with liver/body ratios of all mice 
used in this study (r = 0.54).
Histopathological analysis. We observed 
neither necrosis nor inflammatory cells in 
liver sections from unexposed mice [Table 2, 
Figure 1A–C; see also Supplemental Material, 
Table 2. Severity of hepatic injury by histological score (mean ± SD) in mPPARα, Pparα-null, and hPPARα mice after TRI exposure.
mPPARα Pparα-null hPPARα
Histological parameter Control  TRI 1,000  TRI 2,000 Control  TRI 1,000  TRI 2,000 Control  TRI 1,000 TRI 2,000
Steatosis 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.2 ± 0.1* 1.1 ± 0.2# 1.7 ± 0.5#,† 0.4 ± 0.3* 1.5 ± 0.2# 1.8 ± 0.5#
Necrosis 0.0 ± 0.0 0.7 ± 0.2# 1.2 ± 0.3#,† 0.0 ± 0.0 0.7 ± 0.4# 1.0 ± 0.2# 0.0 ± 0.0 0.6 ± 0.2# 1.0 ± 0.1#,†
Inflammation 0.0 ± 0.0 0.1 ± 0.1 1.0 ± 1.0#,† 0.0 ± 0.0 0.1 ± 0.1 0.3 ± 0.1# 0.0 ± 0.0 0.1 ± 0.2 0.4 ± 0.3#
Hepatocyte proliferation 0.0 ± 0.0 0.2 ± 0.4 0.8 ± 0.4# 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.2 ± 0.4 0.3 ± 0.5
*p < 0.05 compared with the mPPARα control group. #p < 0.05 compared with the control group in the same genotype. †p < 0.05 compared between the 1,000 and 2,000 ppm TRI doses. 
Figure 1. Photomicrographs of representative H&E-stained liver sections from unexposed (A–C) and TRI-treated (D–F) mPPARα (A,D) Pparα-null (B,E), and 
hPPARα (C,F) mice. Abbreviations: CV, central vein; PV, portal vein. Treated mice were exposed to 2,000 ppm TRI. Moderate micro  vesicular steatosis (mi) was 
observed in exposed Pparα-null mice and macrovesicular steatosis (ma) in exposed hPPARα mice. Thick arrows indicate minimal necrosis around the centri-
lobular area, and thin arrows denote inflammatory cells. Bars = 100 µm. 
mPPARα hPPARα Pparα-null
U
n
e
x
p
o
s
e
d
T
R
i
 
(
2
,
0
0
0
 
p
p
m
)Ramdhan et al.
1560  v o l u m e  118 | n u m b e r 11 | November 2010  •  Environmental Health Perspectives
Table 1 (doi:10.1289/ehp.1001928)], which 
is consistent with lower AST and ALT levels 
in these mice (Table 1). However, small cyto-
plasmic vacuoles were present in sections from 
unexposed Pparα-null and hPPARα mice, 
similar to the reports by Wolf et al. (2008) and 
Cheung et al. (2004), respectively, resulting in 
steatosis scores > 0.
Steatosis was absent in the livers of TRI-
exposed and unexposed mPPARα mice, 
but it was significantly increased in exposed 
versus unexposed Pparα-null and hPPARα 
mice; stea  tosis was significantly higher in 
Pparα-null mice exposed to 2,000 versus 
1,000 ppm TRI [Table 2, Figure 1D–F; 
see also Supplemental Material, Table 1 
(doi:10.1289/ehp.1001928)]. Steatosis scores 
were significantly correlated with liver TG 
levels of all mice used in this study (r = 0.75). 
However, macro  vesicular steatosis was more 
common in hPPARα mice than in Pparα-null 
mice. Necrosis scores were significantly higher 
in TRI-exposed mice relative to controls in 
all three genotypes and were significantly 
higher with 2,000 versus 1,000 ppm TRI 
exposure in mPPARα and hPPARα mice. 
Inflammation scores were significantly higher 
than in controls with exposure to 2,000 ppm 
TRI in all three groups and significantly 
higher with 2,000 versus 1,000 ppm TRI in 
mPPARα mice. Hepatocyte proliferation was 
significantly increased with 2,000 ppm TRI 
exposure in mPPARα mice, but there was 
little evidence of an association with exposure 
in hPPARα mice and no evidence of prolif-
eration in Pparα-null mice.
Real-time quantitative PCR. The back-
ground expression of several genes differed 
significantly between strains in control mice 
(Table 3). Specifically, very long chain acyl-
coenzyme A (CoA) dehydrogenase (VLCAD), 
medium chain acyl-CoA dehydrogenase 
(MCAD), peroxisomal bifunctional pro-
tein (hydratase + 3-hydroxyacyl-CoA dehy-
drogenase) (PH), peroxisomal thiolase (PT), 
diacyl  glicerol acyltransferase 1 (DGAT1), and 
p52 mRNA levels were higher in hPPARα 
mice than in mPPARα and Pparα-null mice. 
mRNA levels for PPARα, proliferation cell 
nuclear antigen (PCNA), p50, and tumor 
necrosis factor alpha (TNFα) were higher in 
hPPARα mice than in mPPARα mice, whereas 
PPARγ mRNA was lower in hPPARα mice 
than in Pparα-null mice [Table 3; see also 
Supplemental Material, Figure 1 (doi:10.1289/
ehp.1001928)]. VLCAD, PH, and PT mRNA 
levels were significantly lower in Pparα-null 
mice than in mPPARα mice, and p50, p52, 
PPARγ, and TNFα mRNA levels were higher 
in Pparα-null mice than in mPPARα mice. 
TRI exposure did not increase the expres-
sion of human PPARα mRNA in hPPARα 
mice, but 2,000 ppm TRI significantly 
increased mouse PPARα mRNA in mPPARα 
mice (Table 3). PCNA mRNA expression and 
mRNA expression of the PPARα target genes 
VLCAD, MCAD, PH, and PT were increased 
with TRI exposure relative to controls in 
mPPARα and hPPARα mice, with more pro-
nounced induction of PH and PT mRNA in 
mPPARα mice. However, we observed no 
significant differences in the expression of 
these genes between mice exposed to 1,000 
versus 2,000 ppm TRI.
Relative to unexposed controls, DGAT1 
and DGAT2 mRNA significantly increased 
in hPPARα mice exposed to 2,000 ppm TRI 
and in Pparα-null mice exposed to 1,000 
and 2,000 ppm TRI (Table 3). PPARγ 
mRNA significantly increased in Pparα-
null and hPPARα mice exposed to 1,000 
and 2,000 ppm TRI. In contrast, DGAT1, 
DGAT2, and PPARγ mRNA levels did not 
differ with TRI exposure in mPPARα mice.
NFκB-p65 mRNA expression was signifi-
cantly increased with TRI exposure in Pparα-
null and hPPARα mice but not in mPPARα 
mice (Table 3). NFκB-p50 mRNA expres-
sion was significantly increased with expo-
sure in Pparα-null mice only, but NFκB-p52 
and TNFα mRNA expression was signifi-
cantly increased with exposure in all strains. 
NFκB-p52 mRNA levels were significantly 
Table 3. mRNA and protein expression of several genes.
mPPARα mice Pparα-null mice hPPARα mice
TRI (ppm) TRI (ppm) TRI (ppm)
Control 1,000 2,000 Control A 1,000 2,000 Control B C 1,000 2,000
mRNA
PPARα 0.024 ± 0.008 – 1.5 1.95 ± 0.43 82 –  –
VLCAD  0.59 ± 0.07 1.3 1.6 0.29 ± 0.06 0.49 – – 0.83 ± 0.07 1.4 2.9 1.4 1.3
MCAD  0.30 ± 0.04 1.7 1.9 0.29 ± 0.08 – – – 0.42 ± 0.15 1.4 1.4 1.5 –
PH 0.51 ± 0.16 18.4 17.5 0.45 ± 0.17 0.88 – – 2.1 ± 1.1 4.1 4.6 5.4 5.6
PT 0.40 ± 0.07 4.2 4.4 0.21 ± 0.06 0.51 – – 1.0 ± 0.5 2.5 4.9 2.3 2.2
PCNA (×10–2) 3.8 ± 1.5 1.8 1.9 5.9 ± 1.3 1.5 – –  7.3 ± 2.3 1.9 – 1.5 1.7
DGAT1 0.24 ± 0.03 – – 0.26 ± 0.04 – 1.5 1.5 0.33 ± 0.09 1.4 1.3 – 1.7
DGAT2 0.68 ± 0.16 – – 0.80 ± 0.16 – 1.4 1.5 0.83 ± 0.27 – – 1.2 1.4
PPARγ (×10–5) 5.4 ± 6.5 – – 15.0 ± 7.5 2.8 2.0 2.8 4.5 ± 3.1 – 0.3 2.5 2.5
NFκB-p65 (×10–2) 5.7 ± 0.8 – – 6.4 ± 1.8 – 1.6 1.5 7.5 ± 2.2 – – 1.5 1.4
NFκB-p50 10.0 ± 1.1 – – 14.9 ± 1.2 1.5 1.4 1.3 13.0 ± 2.5 – – – –
NFκB-p52 (×10–3) 2.9 ± 0.3 1.4 1.5 3.4 ± 0.5 1.2 1.6 1.6 4.0 ± 0.9 1.4 1.2 – 1.4
TNFα (×10–5)  2.0 ± 1.8 2.4 2.5 6.5 ± 2.0 3.3 – 1.8 7.3 ± 2.2 3.7 – 1.7 1.5
Protein
PPARα 0.58 ± 0.05 – – 6.1 ± 0.6 10.4 – –
VLCAD 0.43 ± 0.12 5.3 4.9 0.33 ± 0.04 – – – 1.3 ± 0.1 3.0 3.9 1.8 1.8
MCAD 1.7 ± 0.2 – – 1.2 ± 0.1 0.69 – – 1.1 ± 0.1 0.64 – 1.3 1.3
PH 0.64 ± 0.13 4.8 4.1 0.45 ± 0.10 0.71 – – 0.56 ± 0.12 – – 4.3 4.6
PT 0.76 ± 0.14 3.7 3.7 0.61 ± 0.06 0.81 – – 1.5 ± 0.1 2.0 2.5 1.7 1.6
ACOX A 1.5 ± 0.2 1.8 1.7 0.94 ± 0.09 0.62 – – 2.2 ± 0.2 1.5 2.4 1.2 1.3
ACOX B 2.0 ± 0.3 1.5 1.5 1.5 ± 0.1 0.75 – – 2.6 ± 0.3 1.3 1.8 – 1.2
PCNA  0.50 ± 0.14 2.4 2.3 0.36 ± 0.09 0.72 1.8 1.9 0.39 ± 0.14 –   – 2.3 2.6
NFκB-p65 0.88 ± 0.23 – – 1.5 ± 0.3 1.8 1.5 1.4 0.96 ± 0.18 – 0.62 – –
NFκB-p50 0.48 ± 0.14 – – 0.43 ± 0.07 – – 1.4 0.44 ± 0.17 – – – –
NFκB-p52 0.42 ± 0.08 1.8 1.9 0.60 ± 0.14 1.4 1.2 1.5 0.49 ± 0.12 – – 1.5 1.6
TNFα 0.32 ± 0.11 2.2 2.4 0.35 ± 0.13 – 1.7 2.5 0.30 ± 0.09 – – 2.3 2.5
4–HNE 5.2 ± 0.7 – 1.4 5.5 ± 0.7 – 1.4 – 5.2 ± 0.7 – – – 1.3
ALDH2 2.3 ± 0.1 0.69 0.74 2.7 ± 0.2 – 0.66 0.57 2.4 ± 0.2 – – 0.56 0.64
Abbreviations: –, no significant differences were observed; A, Pparα-null mice/mPPARα mice; B, hPPARα mice/mPPARα mice; C, hPPARα mice/Pparα-null mice. Control values represent 
the mean ± SD for five or six mice. Values for other exposure groups represent the fold change compared with the control of that group.Role of PPARα in trichloroethylene-induced steatosis
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correlated with plasma ALT levels of all mice 
used in this study (r = 0.54).
Protein expression. Protein expression dif-
fered among strains in control mice (Table 3). 
PPARα levels were 10.4 times higher in 
unexposed hPPARα mice than in mPPARα 
mice [see Supplemental Material, Figure 2 
(doi:10.1289/ehp.1001928)]. VLCAD, PT, 
acyl-CoA oxidase (ACOX) A, and ACOX B 
proteins were significantly higher in unex-
posed hPPARα mice than in mPPARα and 
Pparα-null mice, MCAD was lower in unex-
posed hPPARα and in Pparα-null mice than 
in mPPARα mice, and NFκB-p65 was lower 
in hPPARα mice than in Pparα-null mice. 
VLCAD, MCAD, PH, PT, ACOX A, and 
ACOX B expression was slightly lower and 
p65 and p52 expression was slightly higher in 
unexposed Pparα-null versus mPPARα mice.
Relative to controls, TRI exposure (both 
doses) significantly increased PPARα target 
gene proteins VLCAD, PH, PT, ACOX A, 
and ACOX B in mPPARα and hPPARα mice, 
but TRI exposure did not induce PPARα 
protein expression. MCAD protein was sig-
nificantly increased with TRI exposure in 
hPPARα mice only. PCNA protein was higher 
in TRI-exposed mice compared with controls 
in all strains. NFκB-p52 and TNFα proteins 
were also increased with TRI exposure in all 
strains, whereas NFκB-p50 and -p65 proteins 
were increased only in exposed Pparα-null 
mice. 4-Hydroxy-2-nonenal protein, a marker 
of oxidative stress, was increased in Pparα-
null mice exposed to 1,000 ppm TRI and 
in mPPARα and hPPARα mice exposed to 
2,000 ppm TRI. 
Additionally, we measured hepatic protein 
expression of CYP2E1 and ALDH2 enzymes, 
as urine TCA levels were significantly lower 
in Pparα-null than in mPPARα mice. We 
did not observe significant differences in the 
expression of either enzyme among controls 
(data not shown). TRI exposure did not influ-
ence hepatic CYP2E1 expression, but it did 
decrease ALDH2 expression to a comparable 
extent in all mouse lines (data not shown).
Discussion
Pparα-null and hPPARα mice appeared to 
be more susceptible to TRI toxicity than 
wild-type mPPARα mice, which suggests 
that PPARα may help protect mice against   
TRI-induced hepatotoxicity, especially from 
lipid accumulation. In particular, we noted 
increased liver TG levels and steatosis with TRI 
exposure in Pparα-null and hPPARα mice, but 
not in mPPARα mice. In contrast, PPARα 
did not appear to influence plasma AST or 
ALT concentration or the severity of hepato-
cyte necrosis and inflammation due to TRI 
exposure, because those responses were compa-
rable across the three mouse lines. Significant 
correlations of ALT and AST responses with 
NFκB-p52 levels underscore the importance 
of this proinflammatory factor in TRI-induced 
hepatic damage, as demon  strated previously 
(Ramdhan et al. 2008), although in Pparα-
null mice, NFκB-p65 and -p50 were also ele-
vated after TRI exposure. However, we did 
not observe substantial differences in ALT, 
AST, NFκB-p52, or TNFα levels between 
mice exposed to the two TRI doses (1,000 and 
2,000 ppm), regardless of genotype, and we 
did not observe dose-related differences in the 
expression of PPARα-target genes in mPPARα 
or hPPARα mice. These results, along with 
evidence that hepatic CYP2E1 expression and   
levels of TRI metabolites (TCA and TCE) 
were comparable among the three strains, may 
be consistent with a role of hepatic CYP2E1 in 
TRI-induced hepatic damage.
Mouse and human PPARα were both 
activated by TRI exposure, but the functional 
consequences of activation differed substan-
tially between mouse and human PPARα, 
with significantly higher PT and PH mRNA 
and protein induction by TRI exposure in 
mPPARα than in hPPARα mice. Similar 
results were also observed after exposure to 
the PPARα agonist Wy-14,643 (Cheung 
et al. 2004). TRI exposure caused significant 
increases in NFκB-p65 and -p50 expression 
in Pparα-null mice but had no effect on either 
factor in mPPARα mice, consistent with com-
plete inhibition of this response by mouse 
PPARα. Human PPARα appeared to be less 
effective in inhibiting this pathway, because 
TRI exposure did induce significant increases 
in NFκB-p65 expression in hPPARα mice. 
Additionally, we observed comparable levels of 
the TRI metabolite and PPARα ligand TCA 
in the livers of mPPARα and hPPARα mice, 
which suggests that differences are not related 
to differences in hepatic exposures between 
the two strains. Nakamura et al. (2009) also 
reported that human PPARα activation by 
microgram-order perfluoro  octanoate, a ligand 
of PPARα, was weaker than mouse PPARα 
activation in response to the same ligand. 
Taken together, these results suggest func-
tional differences between human and mouse 
PPARα. However, such differences were not 
observed in a cell transfection study (Maloney 
and Waxman 1999).
There is some evidence that PPARα acti-
vation inhibits NFκB-p65 and p50 (Delerive 
et al. 1999) and protects against liver injury. 
Our finding that hepatocyte necrosis and 
inflammatory cell infiltrations were compa-
rable after TRI exposure in all three mouse 
strains suggests that PPARα might not be 
important in protecting against the hepatic 
damage induced by TRI, although we did 
observe a slight increase in NFκB-p65 and 
-p50 expression after exposure in Pparα-
null mice. On the other hand, TRI exposure 
was associated with significant increases in 
NFκB-p52 expression in all three mouse lines, 
consistent with a previous study (Ramdhan 
et al. 2008) and with increased expression 
of the proinflammatory cytokine TNFα. 
Together, these two factors may then trigger a 
chain reaction (Elsharkawy and Mann 2007). 
However, because NFκB and TNFα mRNA 
and their proteins were measured using total 
liver homogenates, we could not distinguish 
whether the increases were derived from 
Kupffer cell or hepatocyte responses.
The most intriguing result of the pres-
ent study may be that, although TRI expo-
sure induced enzyme levels involved in the 
β-oxidation system to the same degree in both 
mPPARα and hPPARα mice, the hepatic TG 
levels in hPPARα mice were increased by 
TRI exposure in a manner similar to those in 
Pparα-null mice, but not in mPPARα mice. 
Histopathological findings also showed that 
after TRI exposures, lipid accumulation was 
increased in hPPARα and Pparα-null mice 
compared with mPPARα mice. TRI expo-
sure significantly increased the expression of 
DGAT1 and DGAT2 genes involved in TG 
synthesis (Yen et al. 2008) in hPPARα but 
not mPPARα mice, suggesting that these 
genes may contribute to TG accumula-
tion in the livers of TRI-exposed hPPARα 
mice. In Pparα-null mice, hepatic TG and 
lipid accumulation resulting from a lack of 
PPARα-mediated fatty acid catabolism may 
be exacerbated due to elevated DGAT1 and 
DGAT2 expression in response to TRI expo-
sure. Hepatic TG and lipid accumulations 
were observed most clearly in Pparα-null 
mice, followed by hPPARα mice, consistent 
with an important role of TG-synthesizing 
enzymes in TRI-induced fat accumulation. 
TRI-induced effects of DGAT1 and DGAT2 
appeared to be negatively related to PPARα 
activation. However, PPARγ was reported 
to increase expression of these two genes in 
rats (Festuccia et al. 2009). TRI induced 
hepatic PPARγ-mRNA in Pparα-null mice, 
albeit only slightly in hPPARα mice and not 
at all in mPPARα mice. Thus, mouse PPARα 
may inhibit the activation of PPARγ, with the 
result that PPARγ may not be induced in the 
livers of mPPARα mice.
Hepatic TG levels were different among 
the three strains in the absence of TRI expo-
sure, with the highest levels in hPPARα mice 
and the lowest in mPPARα mice. This sug-
gests that the human PPARα insertion did not 
restore proper lipid regulation in the liver, but 
instead resulted in receptor over  expression that 
exacerbated lipid dys  regulation by increasing 
TG storage and steatosis. Higher constitutive 
expression of DGAT1 may contribute to these 
effects, but further experiments are needed to 
pinpoint the underlying mechanism.
Similar to results in an earlier study 
(Ramdhan et al. 2008), we observed a marked Ramdhan et al.
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hepatomegaly in mPPARα mice exposed to 
TRI that may be due to cellular hypertrophy 
resulting from increased numbers of peroxi-
somes (Nakajima et al. 2000). However, we 
did not observe cell hypertrophy after TRI 
exposure in Pparα-null and hPPARα mice, 
which suggests that hepatomegaly (as indicated 
by increased liver/body weight ratios) may 
have been caused by lipid accumulation rather 
than peroxisome proliferation. Taken together, 
the underlying mechanism for TRI-induced 
hepatomegaly in Pparα-null and hPPARα 
mice was different from that in mPPARα 
mice. Although Laughter et al. (2004) did 
not observe an increase in liver/body weight 
ratio after TRI exposure in Pparα-null mice, 
Nakajima et al. (2000) reported a result simi-
lar to ours. Discrepancies in the nature of the 
hepatomegaly caused by TRI exposure may 
reflect differences in exposure routes, duration, 
or number of animals used in different studies.   
We measured the cell proliferation marker 
PCNA (Dietrich 1993) to further investi-
gate hepatocyte proliferation in response to 
TRI exposure and found that PCNA mRNA 
increased with TRI exposure in mPPARα and 
hPPARα mice but not in Pparα-null mice, 
although PCNA protein expression increased 
with exposure in three groups. However, we 
observed histopathological evidence of hepato-
cyte proliferation in response to TRI exposure 
in mPPARα mice only. This phenomenon 
should be investigated further.
With regard to TRI metabolism, urinary 
TCA levels in Pparα-null mice were signifi-
cantly lower than in mPPARα mice after TRI 
exposure. To clarify the mechanism underly-
ing the lower TCA levels, we meas  ured expres-
sion of the ALDH2 protein involved in the 
metabo  lism of chloral hydrate to TCA because 
TRI has been reported to inhibit ALDH 
expression and activity (Wang et al. 1999); we 
found that ALDH2 was reduced to the same 
degree after TRI exposure in all three strains 
of mice. Crabb et al. (2001) reported that the 
PPARα agonist Wy-14,643 also reduced the 
ALDH2 protein levels by 20–30% in both 
wild-type and Pparα-null mice. Because 
hepatic ALDH2 protein expression was 
inhibited by TRI exposure in all three mouse 
strains, it is an unlikely cause of the decreased 
urinary levels of TCA in Pparα-null mice. 
Other ALDH isozymes may be involved, and 
further experiments are therefore needed.
In the present study, the differences in 
background levels of gene expression between 
unexposed mPPARα and hPPARα mice 
must be duly noted, along with differences 
in TRI-induced changes in mPPARα mice 
observed between the present study and past 
studies (Ramdhan et al. 2008) and discrepan-
cies between mRNA and protein expression 
for some genes. The replacement of human 
PPARα in this study model may not have been 
sufficient to prevent stea  tosis and other effects 
observed in Pparα-null mice; differences in 
responses between mPPARα and hPPARα 
mice may reflect functional consequences 
related to the use of an artificial construct of 
the reinserted gene, without normal control 
elements, in addition to or instead of true func-
tional differences between human and mouse 
PPARα. It also appears that the over  expression 
of human PPARα in this model may lead to 
greater background toxicity than is present in 
the Pparα-null mice, as indicated by steatosis. 
We also found differences in gene expression 
between unexposed mPPARα and hPPARα 
mice. Specifically, VLCAD, MCAD, PH, PT, 
DGAT1, PCNA, p52, and TNFα mRNA levels 
were higher in hPPARα mice than in mPPARα 
mice, whereas PH and TNFα proteins were 
comparable, suggesting that mRNA and pro-
tein levels do not always correspond with each 
other, as noted by Ito et al. (2007). Differences 
in effects of TRI exposure observed between 
the present and our past study (Ramdhan 
et al. 2008) included less-pronounced induc-
tion of PPARα by TRI exposure and more- 
pronounced increases in PH protein and 
VLCAD mRNA expression and ALT and AST 
levels in response to TRI exposure in our previ-
ous study using cyp2e1+/+ mice. We also note 
that urinary TCA levels for mPPARα mice 
after exposure that we incorrectly reported in 
our previous study (Ramdhan et al. 2008) have 
been corrected here. Therefore, although all ele-
ments meas  ured were not completely the same, 
the two studies are consistent overall. Finally, 
our study was limited by the small number of 
mice in each group, which may have limited 
our power to identify statistically significant 
biological effects.
Conclusions
CYP2E1 appears to be involved in the genera-
tion of intermediate metabolites through 
which TRI induces liver injury in mice. In 
contrast, PPARα, and accordingly PPARγ, 
may be important factors in TRI-induced lipid 
accumulation in the liver. Because we used 
genetically modified mice with under  lying 
dys  regulation and we evaluated very high TRI 
exposures that proved systemically toxic, our 
findings may not directly reveal the difference 
in “human PPARα function” as determined 
between mice and humans. Still, evidence of 
TRI toxicity independent of PPARα status 
provides valuable information regarding the 
effects of PPARα genetic manipulation.
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